Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015 - 14/07/19
, Guillaume Cayla, MD, PhD b, Yves Cottin, MD, PhD c, Meyer Elbaz, MD, PhD d, Patrick Henry, MD, PhD e, Edouard Gerbaud, MD, PhD f, Gilles Lemesle, MD, PhD g, Batric Popovic, MD, PhD h, Jean-Noel Labèque, MD i, François Roubille, MD, PhD j, Stéphane Andrieu, MD k, Bruno Farah, MD l, François Schiele, MD, PhD m, Jean Ferrières, MD, PhD n, Tabassome Simon, MD, PhD o, Nicolas Danchin, MD, PhD aon behalf of the USIC and FAST-MI investigators
Background |
The increased use of reperfusion therapy in ST-segment-elevation myocardial infarction (STEMI) patients in the past decades is generally considered the main determinant of improved outcomes. The aim was to assess 20-year trends in profile, management, and one-year outcomes in STEMI patients in relation with use or non-use of reperfusion therapy (primary percutaneous coronary intervention (pPCI) or fibrinolysis).
Methods |
We used data from 5 one-month French nationwide registries, conducted 5 years apart from 2005 to 2015, including 8579 STEMI patients (67% with and 33% without reperfusion therapy) admitted to cardiac intensive care units in France.
Results |
Use of reperfusion therapy increased from 49% in 1995 to 82% in 2015, with a shift from fibrinolysis (37.5% to 6%) to pPCI (12% to 76%). Early use of evidence-based medications gradually increased over the period in both patients with and without reperfusion therapy, although it remained lower at all times in those without reperfusion therapy. One-year mortality decreased in patients with reperfusion therapy (from 11.9% in 1995 to 5.9% in 2010 and 2015, hazard ratio [HR] adjusted on baseline profile 0.40; 95% CI: 0.29-0.54, P < .001) and in those without reperfusion therapy (from 25.0% to 18.2% in 2010 and 8.1% in 2015, HR: 0.33; 95% CI: 0.24-0.47, P < .001).
Conclusions |
In STEMI patients, one-year mortality continues to decline, both related to increased use of reperfusion therapy and progress in overall patient management. In patients with reperfusion therapy, mortality has remained stable since 2010, while it has continued to decline in patients without reperfusion therapy.
Le texte complet de cet article est disponible en PDF.Plan
Vol 214
P. 97-106 - août 2019 Retour au numéro
Article précédent
- Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States
- Thomas A. Gaziano, Ankur Pandya, Stephen Sy, Thiago Veiga Jardim, Jenna M. Ogden, Anthony Rodgers, Milton C. Weinstein
- Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry
- Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Shuang Li, Salim S. Virani, Zhuokai Li, Jennifer G. Robinson, Veronique L. Roger, Peter W.F. Wilson, Anne C. Goldberg, Andrew Koren, Michael J. Louie, Eric D. Peterson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?